A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

NCT05931380 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

238

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company